EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Design and synthesis of 2',3'-dideoxy-2',3'-didehydro-beta-L-cytidine (beta-L-d4C) and 2',3'-dideoxy 2',3'-didehydro-beta-L-5-fluorocytidine (beta-L-Fd4C), two exceptionally potent inhibitors of human hepatitis B virus (HBV) and potent inhibitors of human immunodeficiency virus (HIV) in vitro



Design and synthesis of 2',3'-dideoxy-2',3'-didehydro-beta-L-cytidine (beta-L-d4C) and 2',3'-dideoxy 2',3'-didehydro-beta-L-5-fluorocytidine (beta-L-Fd4C), two exceptionally potent inhibitors of human hepatitis B virus (HBV) and potent inhibitors of human immunodeficiency virus (HIV) in vitro



Journal of Medicinal Chemistry 39(9): 1757-1759




(PDF emailed within 0-6 h: $19.90)

Accession: 045733312

Download citation: RISBibTeXText

PMID: 8627596

DOI: 10.1021/jm950836q



Related references

Design and synthesis of 2,3-dideoxy-2,3-didehydro-beta-L-cytidine and 2,3-dideoxy-2,3-didehydro-beta-L-5-fluorocytidine , two exceptionally potent inhibitors of human hepatitis B virus and potent inhibitors of human immunodeficiency virus in vitro. Journal of Medicinal Chemistry 39(9): 1757-1759, 1996

Antiviral activity of 2',3'-dideoxy-beta-L-5-fluorocytidine (beta-L-FddC) and 2',3'-dideoxy-beta-L-cytidine (beta-L-ddC) against hepatitis B virus and human immunodeficiency virus type 1 in vitro. Biochemical Pharmacology 47(2): 171-174, 1994

Antiviral activity of 2,3-dideoxy-beta-L-5-fluorocytidine and 2,3-dideoxy-beta-L-cytidine against hepatitis B virus and human immunodeficiency virus type 1 in-vitro. Biochemical Pharmacology 47(2): 171-174, 1994

Metabolism of 2',3'-dideoxy-2',3'-didehydro-beta-L(-)-5-fluorocytidine and its activity in combination with clinically approved anti-human immunodeficiency virus beta-D(+) nucleoside analogs in vitro. Antimicrobial Agents and ChemoTherapy 42(7): 1799-1804, 1998

In vitro selection and analysis of human immunodeficiency virus type 1 resistant to derivatives of beta-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine. Antimicrobial Agents and ChemoTherapy 49(9): 3930-3932, 2005

Studies of the pharmacokinetics and toxicology of 2',3'-dideoxy-beta-L-5-fluorocytidine (beta-L-FddC) and 2',3'-dideoxy-beta-L-cytidine (beta-L-ddC) in vivo; and synthesis and antiviral evaluations of 2',3'-dideoxy-beta-L-5-azacytidine. Nucleosides and Nucleotides 14(3-5): 619-625, 1995

A stereospecific synthesis of 2,3-dideoxy-beta-L-cytidine , a potent inhibitor against human hepatitis B virus and human immunodeficiency virus. Tetrahedron Letters 35(21): 3477-3480, 1994

The effects of the beta-D and beta-L enantiomers of 2,3-dideoxy-2,3-didehydro-5-fluorocytosine triphosphate on the synthesis of Duck Hepatitis B Virus primer DNA in vitro. Antiviral Research 37(3): A45, March, 1998

Studies of the pharmacokinetics and toxicology of 2,3-dideoxy-beta-L-5-fluorocytidine and 2,3-dideoxy-beta-L-cytidine in vivo; and synthesis and antiviral evaluations of 2,3-dideoxy-beta-L-5-azacytidine. Nucleosides & Nucleotides 14(3-5): 619-625, 1995

Anti-hepatitis B virus activity and metabolism of 2',3'-dideoxy-2',3'-didehydro-beta-L(-)-5-fluorocytidine. Antimicrobial Agents and ChemoTherapy 42(7): 1805-1810, 1998

Anti-hepatitis B virus action and metabolism of 2-3-dideoxy-2,3-didehydro-beta-L -5-fluorocytidine. Proceedings of the American Association for Cancer Research Annual Meeting 39: 602, March, 1998

Interaction of beta-L-2',3'-dideoxy-2',3'-didehydro-5-fluoro-CTP with human immunodeficiency virus-1 reverse transcriptase and human DNA polymerases: Implications for human immunodificiency virus drug design. Molecular Pharmacology 53(5): 801-807, 1998